■ MANTIS

CDMO, Small Molecule
& Bioprocess Intelligence
Updated 13 June 2026  ·  75 companies monitored
1,603
Signals
30 days
75
Companies
tracked
162
Predictions
logged
Leading narrative Biosimilar Market Expansion Rolling 7 days
Leading tech themeSmall MoleculePatent & publication signals · 30 days
Story of the week
↗ Accelerating Biosimilar Market Expansion
544signals this week · 29companies active
Signal of the week
FDA Action ●●●●○○○○  4/10
Drug Approval: ATOVAQUONE (manufactured by Lupin)
Narrative tracker — signals · rolling 7 days
01Biosimilar Market Expansion544
02GLP-1 Manufacturing Capacity438
03Cell & Gene Therapy Manufacturing411
04India Generics & API Expansion326
05Sector Consolidation & M&A222
06ADC Outsourcing Wave165
07Manufacturing Capacity Expansion135
08Generic & Biosimilar Market Dynamics99
09Next-Gen Manufacturing Technology58
10Nucleic Acid Manufacturing47
Narrative momentum — rolling 30 days
Narrative momentum — 30 days

Each line tracks one sector narrative — 7-day rolling average of signal volume and cross-source breadth, updated daily.

This week in pharma manufacturing
📰Incyte inks $2B deal to add Star unit to late-phase constellation and challenge TakedaStrides Pharma Sciencefiercebiotech.comM&A 📰WuXi AppTec hits back after being named in Pentagon’s Chinese military listWuXi AppTecpharmaceutical-technology.com
Deal intelligence — partnerships & capacity moves
🤝Incyte inks $2B deal to add Star unit to late-phase constellation and challenge TakedaStrides Pharma Science5
Demand drivers — pharma pipeline signals Pharma pipeline signals
📈Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdownBristol Myers Squibb4 📈ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetesEli Lilly4 📈ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestoneNovo Nordisk4 📈ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowessMerck2 📈Novo Nordisk puts AI at the centre of its clinical strategyNovo Nordisk2 📈AbbVie receives EC approval for Aquipta to treat migraineAbbVie2
How it works
01
Collect
Signals ingested daily across clinical trials, FDA and EMA regulatory filings, scientific publications, SEC disclosures, hiring patterns, and industry news. Each signal is scored and classified by therapy area and signal type.
02
Converge
When multiple independent sources flag the same company within a rolling window, a convergence alert fires. Cross-source agreement is the signal — a single news article is noise; a clinical filing, a hiring surge, and a regulatory action on the same company are not.
03
Synthesise
A weekly synthesis covers what moved, what it implies, and where to look next. Predictions are made explicitly and logged — then scored as outcomes become known. Company-level intelligence briefs covering signal momentum, risk flags, and capability profiles are available on request.
Signal sources — rolling 30 days
News840
Clinical Trials410
Science145
Patent Cliff113
FDA44
Hiring42
SEC Filings9

Mantis runs continuously — ingesting signals, scoring convergence, and tracking whether its predictions come true. It does not summarise headlines. It identifies when independent data sources start moving in the same direction on the same company, and asks what that combination of evidence implies. Built for the pharma advisor or investor who needs to know which CDMOs are moving before the headlines explain why.

CDMO selection · competitive intelligence · strategic advice
Intelligence briefings and company assessments available on request.
[email protected] →
[email protected] © 2026 Mantis Intelligence.

Mantis Intelligence is not authorised or regulated by the Financial Conduct Authority or any other financial regulator. Content is produced by automated systems and artificial intelligence for information and research purposes only. Nothing on this site constitutes investment advice, a personal recommendation, or a solicitation. Past signal patterns are not predictive of future events or outcomes.

Signals are sourced from public regulatory filings (FDA, EMA, SEC EDGAR), clinical trial registries, scientific publication databases, and publicly available news feeds. This site sets no cookies and collects no personal data.